公司财务状况 - 公司在2022年12月31日的净亏损为7,660万美元[234] - 公司在2022年12月31日的累计赤字为4.604亿美元[234] - 公司的财务结果会受到多种因素的影响，包括市场推广、新诊断解决方案的商业化、研发支出、第三方支付的现金收款时间等[288] - 如果公司季度运营结果低于投资者或证券分析师的预期，股价可能会大幅下跌[290] - 公司的营收从2.964亿美元增长至3.218亿美元，年增长率为9%[318] - 公司的未来营收增长将取决于多个因素，包括当前和未来解决方案的持续使用和接受程度，对测试服务、产品和患者数字解决方案的需求，以及新产品或服务的推出和接受程度[318] 法律诉讼风险 - 公司可能会面临法律诉讼，这可能会耗费大量时间和资源，并对业务、财务状况和运营结果产生不利影响[264] - 公司曾涉及诉讼，未来可能继续涉及，例如对Natera提起的虚假广告诉讼，法院判决公司获得4490万美元赔偿[265] - 公司对Natera的专利侵权诉讼未获胜，美国联邦巡回上诉法院维持了法院对公司的判决[266] - 公司面临来自Natera的专利侵权诉讼，公司表示将积极辩护，但无法保证胜诉[267] - 公司面临来自Plumbers & Pipefitters Local Union 295 Pension Fund的证券集体诉讼，公司表示将积极辩护，但无法保证胜诉[268] - 公司面临来自Oklahoma Police Pension and Retirement System领导的投资者集团的诉讼，公司表示将积极辩护，但无法保证胜诉[269] - 公司面临来自Jeffrey Edelman和Jaysen Stevenson的股东衍生诉讼，公司表示将积极辩护，但无法保证胜诉[270] 市场竞争和风险 - 未来解决方案的采用率和报销率可能会受到科学和医学期刊中的研究支持的影响[291] - 临床效用研究的管理费用昂贵，需要公司管理团队的重视[292] - 与临床监测领域中更大更成熟的竞争对手竞争可能会影响公司的收入和盈利能力[297] - 公司的AlloSure Kidney解决方案与其他诊断测试存在竞争，需要继续教育临床医生和支付方[298] - 公司预计移植前型和移植后监测的竞争将增加，可能会影响市场份额和利润率[300] - 公司需要不断更新产品，否则可能影响吸引和保留客户的能力[305] 公司风险管理 - 公司可能面临投资者对其环境、社会和治理因素表现的期望，这可能会增加成本并使公司面临新风险[325] - 公司的资金需求将取决于多个因素，包括开发新解决方案所需的研发投资水平、专利申请和维护成本、竞争性技术和市场发展等[335] - 公司可能会通过收购、技术许可安排或战略联盟来扩展现有的专业知识和知识产权[345] - 未来的收购可能导致债务、摊销费用、额外运营费用或商誉和其他无形资产的减值，可能会损害公司的业务和运营结果[347] - 公司可能选择发行普通股作为收购的对价，这可能会稀释股东的利益[348]

CareDx, Inc (NASDAQ:CDNA) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Brandon Couillard - Jefferies Operator Good day, ladies and gentlemen, and welcome to the CareDx, Incorporated Third Quarter 2022 Earnings Conference Call. TodayÂ's conference is being recorded. At this time, I would like to turn the conference over to Ian Cooney. Please go ahead. Ian Cooney Good afternoon, an ...

| --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------|-------|-----------|-------|-----------------------------|-------|-------| | | | | | | | | | Focused on improving care across the entire transplant patient journey The Transplant Company Q3 2022 | ™ | | | | | | | | | Leslie M, | | Kidney Transplant Recipient | | | | Earnings Presentation | | | | | | | Safe Harbor Statement These slides and the accompanying ora ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-365 ...

CareDx, Inc. (NASDAQ:CDNA) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Ian Cooney - VP, IR Reg Seeto - CEO Abhishek Jain - Interim CFO Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Brandon Couillard - Jefferies Jacob Johnson - Stephens Yi Chen - H.C. Wainwright E.V. Koslosky - Goldman Sachs Operator Good day, and welcome to the CareDx, Inc. Second Quarter 2022 Earnings Call. TodayÂ's conference is being recorded. At this ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36536 __ ...

CareDx, Inc (NASDAQ:CDNA) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Ian Cooney - VP of IR Reg Seeto - CEO Ankur Dhingra - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Andrew Cooper - Raymond James Mason Carrico - Stephens Inc. Operator Good day, and welcome to the CareDx First Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] Please note this event is being recorded. I would now like to turn t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________ FORM 10-Q __________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36536 _ ...

CareDx, Inc (NASDAQ:CDNA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Ian Cooney - Vice President of Investor Relations Reg Seeto - President & Chief Executive Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Dipesh Patel - H.C. Wainwright Andrew Cooper - Raymond James Operator Thank you for standing by. This is the conference operator. Welcome to the CareDx, Inc. Fourth Quarter 2021 Earnings Conferenc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________________________ Form 10-K ________________________________________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF TH ...